Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MF59 H1N1 vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Vaccine | ACTIVE_COMPARATOR | adjuvanted influenza vaccine |
| Vaccine 2 | ACTIVE_COMPARATOR | non-adjuvanted vaccine |
| Name | Type | Description |
|---|---|---|
| MF59 H1N1 vaccine | BIOLOGICAL | 3.75-7.5ug dose |
| Plain H1N1 vaccine | BIOLOGICAL | 7.5-15ug |
Inclusion Criteria: 1. Mentally competent adults, who have signed an informed consent form after having received a detailed explanation of the study protocol. 2. Male or female subjects 18-50 years who are either healthy or have a stable medical condition. 3. Able to understand and comply with all ...
MF59 H1N1 vaccine is an investigational vaccine being studied for the prevention of influenza. It is currently in Phase 1 clinical development, meaning it has not yet been approved for use. The vaccine is designed to generate an immune response against the H1N1 strain of the influenza virus.
MF59 H1N1 vaccine is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine.
MF59 H1N1 vaccine is in Phase 1 clinical development. This early-stage trial is designed to assess the safety and immune response of the vaccine in healthy adults. The vaccine is investigational and has not received regulatory approval for public use.
MF59 H1N1 vaccine has one completed clinical trial registered as NCT00943358, titled 'Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults.' This Phase 1 study enrolled 175 participants in the United Kingdom and evaluated the vaccine's safety and immunogenicity in healthy adults aged 18 years and older.
MF59 H1N1 vaccine is a specific investigational vaccine formulation targeting the H1N1 influenza strain. It is being studied as a potential vaccine for influenza, but it is not yet approved. The vaccine is distinct from other H1N1 vaccines due to its specific formulation and development by Novartis.